Back
Gyre Therapeutics, Inc. 10K Form
Sell
47
GYRE
Gyre Therapeutics, Inc.
Last Price:
$6.81
Seasonality Move:
12.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive GYRE News And Ratings
See the #1 stock for the next 7 days that we like better than GYRE
GYRE Financial Statistics
Sales & Book Value
| Annual Sales: | $105.8M |
|---|---|
| Cash Flow: | $4.3M |
| Price / Cash Flow: | 528.63 |
| Annual Sales: | $1.12 |
| Price / Book: | 6.44 |
Profitability
| EPS (TTM): | 0.03800 |
|---|---|
| Net Income (TTM): | $11.8M |
| Gross Margin: | $101.9M |
| Return on Equity: | 10.4% |
| Return on Assets: | 8.53% |
Gyre Therapeutics, Inc. Earnings Forecast
Key Gyre Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 23 years for GYRE is 96.33%.
-
The Selling, General & Administrative Expenses for GYRE have been equal to 69.61% of Gross Profit Margin.
-
The Research & Development expenses have been 11.37% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of GYRE is 16.92% of Total Revenues.
-
Per Share Earnings over the last 23 years have been positive in 13 years.
Gyre Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | GYRE |
| Website: | gyretx.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 6.19 |
| Quick Ratio: | 5.45 |
Price-to-Earnings
| Trailing P/E Ratio: | 141.58 |
|---|---|
| Forward P/E Ratio: | 29.61 |
GYRE Technical Analysis vs Fundamental Analysis
Sell
47
Gyre Therapeutics, Inc. (GYRE)
is a Sell
Is Gyre Therapeutics, Inc. a Buy or a Sell?
-
Gyre Therapeutics, Inc. stock is rated a SellThe current Gyre Therapeutics, Inc. [GYRE] share price is $7.06. The Score for GYRE is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.